Bio-Rad Laboratories, Inc. Class A Common Stock vs TORM plc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while TORM plc trades at $28.3 (market cap $2.93B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.2× TORM plc's market cap, and TORM plc pays a 9.77% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TRMD | |
|---|---|---|
Market Cap | $9.43B | $2.93B |
Sector | Health | Technology |
52-Week High | $356.25 | $34.87 |
52-Week Low | $241.71 | $18.77 |
Enterprise Value | $9.18B | $3.82B |
Dividend Yield | — | 9.77% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →